Clinical development stage, macromolecule

Finally, pulmonary protein delivery has advanced tremendously since 1990. One local therapy has been approved and a number of others, including insulin, are in the later stages of clinical development. The device platforms that have been developed for these macromolecules have also exhibited higher delivery efficiencies and greater reproducibility than the old technologies, and these attributes may well have application in other areas of pulmonary delivery. For example, they may facilitate delivery of small molecules though the lung for a faster onset of action. 

---